DermaXon targets the brain-skin connection to discover and develop novel therapeutic strategies to treat life-threatening diseases and disorders such as pain, pruritus and genetic disorders of skin keratinization.
The company core technology is based on the design and development of small molecules modulating multiple targets or inhibiting the degradation of endogenous molecules exhibiting polypharmacology. This polypharmacological approaches aim to understand and optimize the unknown off-targets activities for existing small molecules such as cannabinoids or retinoic acid. DermaXon uses medicinal chemistry, molecular biology and RNA sequencing to characterize and identify synergies and overlaps between biological signaling pathways modulated by small molecules.
Company Details
- Employees
- 3
- Founded
- -
- Address
- 32 Campus Dr,
- Industry
- Biotechnology
- Website
- dermaxon.com
- Keywords
- Drug Discovery, Dermatology, Alzheimer's disease, Parkinson's disease, Ichthyosis, Acne, Aging.
- HQ
- Missoula, Montana
Dermaxon Questions
Dermaxon's website is dermaxon.com
Dermaxon's LinkedIn profile is https://www.linkedin.com/company/dermaxon
Dermaxon has
3 employees.
View email and phone details for 3
employees at Dermaxon.
Dermaxon's industry is
Biotechnology
Dermaxon's top competitors are
The Cody Group Inc. A Division Of Choice Financial Group,
Digitekz Studio,
E Fire Usa,
Rocky Mountain Biologicals, Llc,
Amazon,
Phoenix Group,
Inimmune,
Fyr Bio,
Affymax Research Institute,
Dermax.
Dermaxon's categories are Biotechnology
Dermaxon's founding year is 2013
